JP6258918B2 - ヒストンデアセチラーゼ（ｈｄａｃｓ）阻害剤 - Google Patents

ヒストンデアセチラーゼ（ｈｄａｃｓ）阻害剤 Download PDF

Info

Publication number
JP6258918B2
JP6258918B2 JP2015505789A JP2015505789A JP6258918B2 JP 6258918 B2 JP6258918 B2 JP 6258918B2 JP 2015505789 A JP2015505789 A JP 2015505789A JP 2015505789 A JP2015505789 A JP 2015505789A JP 6258918 B2 JP6258918 B2 JP 6258918B2
Authority
JP
Japan
Prior art keywords
oxo
dihydro
hydroxyacrylamide
ethyl
hydroxyamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015505789A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015512939A5 (enExample
JP2015512939A (ja
Inventor
ジーワン チャーン，
ジーワン チャーン，
ユー，チャオウー
チャン，ペイテー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Annji Pharmaceutical Co Ltd
Original Assignee
Annji Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annji Pharmaceutical Co Ltd filed Critical Annji Pharmaceutical Co Ltd
Publication of JP2015512939A publication Critical patent/JP2015512939A/ja
Publication of JP2015512939A5 publication Critical patent/JP2015512939A5/ja
Application granted granted Critical
Publication of JP6258918B2 publication Critical patent/JP6258918B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2015505789A 2012-04-10 2013-04-02 ヒストンデアセチラーゼ（ｈｄａｃｓ）阻害剤 Active JP6258918B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261622127P 2012-04-10 2012-04-10
US61/622,127 2012-04-10
PCT/US2013/035004 WO2013154870A1 (en) 2012-04-10 2013-04-02 Histone deacetylases (hdacs) inhibitors

Publications (3)

Publication Number Publication Date
JP2015512939A JP2015512939A (ja) 2015-04-30
JP2015512939A5 JP2015512939A5 (enExample) 2016-06-02
JP6258918B2 true JP6258918B2 (ja) 2018-01-10

Family

ID=49292802

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015505789A Active JP6258918B2 (ja) 2012-04-10 2013-04-02 ヒストンデアセチラーゼ（ｈｄａｃｓ）阻害剤

Country Status (13)

Country Link
US (2) US9387209B2 (enExample)
EP (1) EP2836484B1 (enExample)
JP (1) JP6258918B2 (enExample)
KR (1) KR101781922B1 (enExample)
CN (1) CN104364237B (enExample)
AU (1) AU2013246278B2 (enExample)
BR (1) BR112014025122B1 (enExample)
ES (1) ES2630062T3 (enExample)
IL (1) IL235053A (enExample)
IN (1) IN2014MN02104A (enExample)
RU (1) RU2629947C2 (enExample)
TW (1) TWI481597B (enExample)
WO (1) WO2013154870A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10052739B2 (en) 2011-09-12 2018-08-21 Applied Materials, Inc. Carrier head with composite plastic portions
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP2017508798A (ja) 2014-03-07 2017-03-30 ザ ジョンズ ホプキンス ユニバーシティ ヒストンリジン特異的デメチラーゼ（ｌｓｄ１）およびヒストンデアセチラーゼ（ｈｄａｃ）の阻害剤
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
US10807944B2 (en) 2014-04-04 2020-10-20 University Of Florida Research Foundation, Inc. HDAC inhibitor compounds and methods of treatment
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP7254028B2 (ja) * 2017-05-16 2023-04-07 アンジー ファーマスーティカル シーオー．，エルティーディー． ヒストンデアセチラーゼ（ｈｄａｃｓ）阻害剤
GB201820450D0 (en) 2018-12-14 2019-01-30 Z Factor Ltd Compound and its use for the treatment of alpha1-antitryspin deficiency
GB201918404D0 (en) * 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of aplha1-antitrypsin deficiency
KR20210116830A (ko) * 2020-03-17 2021-09-28 충북대학교 산학협력단 신규한 4-옥소퀴나졸린-기반 n-하이드록시프로펜아미드 및 이의 용도
CN111517977B (zh) * 2020-05-28 2023-05-23 爱斯特（成都）生物制药股份有限公司 一种合成2,4-二氟-3-三甲基乙酰胺基苯甲酸的方法
MX2022015532A (es) * 2020-06-08 2023-04-04 Annji Pharm Co Ltd Inhibidores selectivos de hdac6 y usos de los mismos.
WO2023159155A1 (en) * 2022-02-18 2023-08-24 Pivalent Therapeutics, Inc. Inhibitors of phosphoinositide 3-kinase (pi3k) and uses thereof
IL326137A (en) 2023-07-28 2026-03-01 Cogent Biosciences Inc PI3K inhibitors
CN120379970A (zh) * 2023-10-18 2025-07-25 太溪生技新药股份有限公司 用于hdac抑制的喹唑啉酮衍生物
WO2026099248A1 (en) * 2024-11-06 2026-05-15 Janssen Pharmaceutica Nv N-phenyl-2-(4-oxo-quinazolin-3(4h)-yl)propanamide derivatives as tmem175 modulators for reducing alpha-synuclein aggregation for the treatment of parkinson's disease

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE666424A (enExample) * 1965-05-12 1966-01-05
FR6001M (enExample) * 1966-12-02 1968-04-29
ZA705270B (en) * 1969-08-02 1971-04-28 Sumitomo Chemical Co Novel quinazolinone derivatives and a process for production thereof
US4054658A (en) 1974-02-06 1977-10-18 William H. Rorer, Inc. Therapeutic compositions containing methaqualone
NZ192392A (en) * 1978-12-19 1983-02-15 M Ishikawa 3-(substituted (phenyl or pyridyl)) -3,4-dihydroquinazolin-4-ones
JP3488890B2 (ja) * 1993-11-09 2004-01-19 アグロカネショウ株式会社 ３−ｎ−置換キナゾリノン誘導体、その製造法および該化合物を含有する除草剤
EP1524262A1 (en) 2000-03-24 2005-04-20 Methylgene, Inc. Inhibitors of histone deacetylase
JP2003528074A (ja) * 2000-03-24 2003-09-24 メチルジーン インコーポレイテッド ヒストン脱アセチル化酵素の阻害剤
WO2004041755A2 (en) * 2002-11-04 2004-05-21 Nps Pharmaceuticals, Inc. Quinazolinone compounds as calcilytics
ITMI20041869A1 (it) 2004-10-01 2005-01-01 Dac Srl Nuovi inibitori delle istone deacetilasi
CN101263125A (zh) * 2005-07-15 2008-09-10 先灵公司 用于癌症治疗的喹唑啉衍生物
EA018698B1 (ru) 2005-09-21 2013-10-30 4Сц Аг Сульфонилпирролгидрохлориды как ингибиторы гистондезацетилазы
GB0525068D0 (en) * 2005-12-08 2006-01-18 Novartis Ag Organic compounds
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
GB0624187D0 (en) 2006-12-04 2007-01-10 Jackson William P HDAC inhibitors
WO2008087514A2 (en) 2007-01-17 2008-07-24 Orchid Research Laboratories Limited Hdac inhibitors
JP2010536876A (ja) 2007-08-21 2010-12-02 アークル インコーポレイテッド Ｈｄａｃインヒビター
CA2700857C (en) 2007-10-01 2016-08-02 John S. Kovach Hdac inhibitors
JP5838157B2 (ja) 2009-07-22 2015-12-24 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ Ｈｄａｃ阻害剤およびそれを用いる治療法

Also Published As

Publication number Publication date
AU2013246278A1 (en) 2014-11-13
BR112014025122B1 (pt) 2022-08-16
EP2836484A1 (en) 2015-02-18
EP2836484B1 (en) 2017-06-14
RU2014144142A (ru) 2016-06-10
ES2630062T3 (es) 2017-08-17
US9155739B2 (en) 2015-10-13
IL235053A (en) 2017-09-28
EP2836484A4 (en) 2015-09-02
RU2629947C2 (ru) 2017-09-05
AU2013246278B2 (en) 2016-11-03
KR101781922B1 (ko) 2017-09-26
US9387209B2 (en) 2016-07-12
US20150196563A1 (en) 2015-07-16
WO2013154870A1 (en) 2013-10-17
US20130267542A1 (en) 2013-10-10
TW201345898A (zh) 2013-11-16
KR20150000901A (ko) 2015-01-05
CN104364237B (zh) 2016-08-24
TWI481597B (zh) 2015-04-21
IN2014MN02104A (enExample) 2015-09-04
BR112014025122A2 (pt) 2021-07-06
CN104364237A (zh) 2015-02-18
JP2015512939A (ja) 2015-04-30

Similar Documents

Publication Publication Date Title
RU2629947C2 (ru) Ингибиторы деацетилаз гистонов (hdacs)
JP7254028B2 (ja) ヒストンデアセチラーゼ（ｈｄａｃｓ）阻害剤
JP2015512939A5 (enExample)
CA2651128A1 (en) Benzimidazole modulators of vr1
WO2019120210A1 (zh) 一类苯并呋喃及Coumestans衍生物及其制备方法和应用
CA2592514A1 (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
CA2709068A1 (en) Benzofuran anilide histone deacetylase inhibitors
CN114685382B (zh) 具有HDACs抑制活性的喹唑啉-4-胺衍生物及其制备方法与用途
BR112013000716B1 (pt) Compostos derivados e análogos de aril e heteroarilquinolin e composição compreendendo os ditos compostos
US20260124191A1 (en) Histone deacetylase inhibitor and uses thereof
JP2011519343A5 (enExample)
CN112390781B (zh) 二芳基取代的1,1-乙烯类化合物、制备方法及用途
KR20100121656A (ko) Ｈｄａｃ 저해제로서의 술포닐피롤의 신규 제조 방법
KR102439852B1 (ko) 2-아미노퀴놀린-8-올 유도체, 및 이의 용도
CN110054619A (zh) 新型二酮哌嗪类组蛋白去乙酰化酶抑制剂
CN109641888B (zh) 一类芳基-2，2′-串联双噻唑类化合物及其制备方法和用途
JP2021529785A (ja) ヘッジホッグ経路に関連する状態の治療のための化合物および方法
Bryant Palladium-catalyzed cyclization of drug candidates
CN104327043B (zh) 一种吖啶硫醚类衍生物及其制备方法和用途
CN117285455A (zh) 2-苯甲酰基吲哚类化合物及其应用
CN107098901A (zh) 具有抗惊厥活性的化合物及其制备方法和应用
CN104327043A (zh) 一种吖啶硫醚类衍生物及其制备方法和用途
SI9300202A (sl) Derivati hidroksikinolona

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160401

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160401

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20161020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161115

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171003

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20171106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171207

R150 Certificate of patent or registration of utility model

Ref document number: 6258918

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R154 Certificate of patent or utility model (reissue)

Free format text: JAPANESE INTERMEDIATE CODE: R154

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250